GRAIL is trading up 4.12% at $142.19 on September 30, extending gains after the September 23 FDA advisory panel backed its Galleri cancer-detection test. - The panel voted 7-2 that benefits outweighed risks, a step toward possible FDA approval; the agency’s final decision is pending. - No new company announcement explaining the move was found. Markets also rose after stronger-than-expected U.S. GDP data, but available evidence points more to continued reaction to the panel vote than a confirmed new catalyst.